HiPSC models offer a promising avenue to tackle the significant challenges inherent in AD research, including disease heterogeneity, the deficiency of personalized therapeutic strategies, and the limited availability of novel therapeutic targets beyond Aβ and tau. The gene discussed is MAPT; the disease is Alzheimer disease.